Navigation Links
Otonomy Appoints Gerald Wroblewski as Chief Operations Officer
Date:5/25/2011

SAN DIEGO, May 25, 2011 /PRNewswire/ -- Otonomy, Inc., a clinical stage biopharmaceutical company developing innovative therapeutics for diseases and disorders of the inner and middle ear, today announced the appointment of Gerald Wroblewski as the company's chief operations officer.  Mr. Wroblewski brings the company broad operational expertise in the areas of manufacturing, product supply chain management, packaging and quality assurance.  At Otonomy, he will be responsible for overseeing activities in these areas to support the advancement of the company's product candidates through clinical development and into commercialization.  The company recently announced plans to initiate a Phase 2 study for its lead drug candidate, OTO-104, in patients with Meniere's disease and is also positioned to begin clinical trials of a second product candidate, OTO-201, by the end of 2011.

Prior to joining Otonomy, Mr. Wroblewski served as vice president of operations at MacuSight, a developer of innovative therapeutics for the treatment of severe ocular diseases and conditions.  In this role, he managed manufacturing and product supply chain activities to support clinical advancement of the company's sustained release, injectable drug candidate.  Before his work with MacuSight, he was chief operating officer at iScience Interventional Inc., a start-up medical device company in the ophthalmology space, and executive vice president of operations at Oculex Pharmaceuticals, a developer of novel biodegradable therapeutics for diseases of the eye.  While at Oculex, Mr. Wroblewski was responsible for developing and implementing GMP manufacturing systems designed to support the production of multiple product components related to the company's sustained release steroid formulation.  These innovative manufacturing platforms supported the advancement of the product into late-stage clinical trials and ultimately contributed to Allergan's
'/>"/>

SOURCE Otonomy, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Otonomys OTO-104 Demonstrates Hearing Loss Protection and Hearing Recovery in Preclinical Studies
2. Otonomy Introduces Scientific Advisory Board
3. Cellectis bioresearch Appoints Wako as Exclusive Distributor of its Genome Customization Solutions in Japan
4. BioNeutral Appoints Michael D. Francis, J.D. as Director to the Board
5. ChromaDex Appoints Curtis Lockshin, Ph.D., to its Board of Directors
6. BioStorage Technologies Appoints New Director of Business Development for European Operations
7. Access Pharmaceuticals Appoints Industry Executive Anthony Mottola as Vice President of Managed Care and Market Access
8. SeraCare Life Sciences Appoints Sean OConnor as Vice President of Sales and Marketing
9. Genesis Biopharma Appoints William H. Andrews Ph.D. to Board of Directors
10. Laureate Biopharma Appoints Ann M. Daus, Ph.D. Vice President, Quality
11. OncoSec Medical Appoints Punit Dhillon as President and CEO
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/11/2014)... 2014 , Not for release, publication ... from any jurisdiction where to do so would constitute a ... Shire plc ("Shire" or the "Company") (LSE: SHP, NASDAQ: ... confirms it has held a meeting with representatives of AbbVie. ... the prior agreement or approval of AbbVie. A ...
(Date:7/11/2014)... 2014 /CNW/ - Sunovion Pharmaceuticals Canada Inc. (Sunovion) today ... acetate) for use as a once-daily adjunctive therapy for ... who are not satisfactorily controlled with conventional therapy.  APTIOM ... under 18 years of age. Epilepsy ... according to Epilepsy Canada, it affects 0.6% of the ...
(Date:7/10/2014)... (PRWEB) July 10, 2014 Product ... in very low abundance and are often “lost ... and time-consuming. , Join presenters Dr. Rowel Tobias, ... Dr. John Anders, Head of Quality at Nanotherapeutics, ... approach that can speed detection and quantitation while ...
(Date:7/10/2014)... CA (PRWEB) July 10, 2014 Unraveling ... closer together. The Archer Family purchased a ... within DNA, but ended up with a lifetime of ... contained within the family members’ DNA genuinely brought the ... decided to search deeper into genetic history and prior ...
Breaking Biology Technology:Shire plc - Statement re: Media Speculation 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 2Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 3Sunovion Pharmaceuticals Canada Inc. Announces Health Canada Approval of APTIOM(TM) (eslicarbazepine acetate) as a Once-Daily Adjunctive Treatment for Partial-Onset Seizures in Patients with Epilepsy 4Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 2Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 3Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 4Ancestry DNA Test Reveals a Controversial and Undiscovered Family History 5
... N.J., July 10 Senesco Technologies , Inc. ... announced that, on July 9, 2009, the Company entered into a ... sale of (i) up to 1,111,111 shares of its common stock ... to purchase an aggregate of up to 1,000,000 shares of common ...
... of Energy,s Lawrence Berkeley National Laboratory and the University ... fabricate efficient solar cells from low-cost and flexible materials. ... of nanoscale pillars, each a single crystal, with dimensions ... take advantage of abundant solar energy we have to ...
... July 9 PharmAthene, Inc. (NYSE Amex: ... biological and chemical threats, today announced that the U.S. ... of the Company,s proposed development plan for SparVax(TM), PharmAthene,s ... , In response to amendments to the request ...
Cached Biology Technology:Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 2Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 3Senesco Technologies Enters Into Agreement For Up To $1.0 Million In Financing 4Nanopillars promise cheap, efficient, flexible solar cells 2Nanopillars promise cheap, efficient, flexible solar cells 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 2PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 3PharmAthene's 2nd Generation rPA Anthrax Vaccine, SparVax(TM), Completes FDA Regulatory Strategy Review 4
(Date:7/11/2014)... of Standards and Technology (NIST) need a special ... often prove that necessity is truly the mother ... M. Lorna De Leoz and Stephen Stein, NIST ... Glycomics is the study of the abundant, often-branched ... proteins and lipids and influence cellular processes, including ...
(Date:7/11/2014)... 3, 2014, Shenzhen, China Researchers from Salk Institute ... the first time evaluated the safety and reliability ... successfully developed a new method, TALEN-HDAdV, which could ... stem cell (hiPSC). This study published online in ... theoretical foundation for stem cell-based gene therapy. , ...
(Date:7/11/2014)... the Max Planck Institute for Medical Research in Heidelberg, ... photosynthesis, the process by which the Earth first gained ... which is therefore crucial for all higher forms of ... first direct visualization of a crucial event in the ... protein complex, photosystem II, splits water into hydrogen and ...
Breaking Biology News(10 mins):A new genome editing method brings the possibility of gene therapies closer to reality 2A first direct glimpse of photosynthesis in action 2
... available in Spanish . Learning more ... used by U.S. Department of Agriculture (USDA) scientists to identify ... bed bugs over the last decade has caused problems in ... and even places of work. The small, blood-feeding insects are ...
... have found that one of the most aggressive invasive ant ... appears to have met its match in the Asian needle ... ant is successfully displacing Argentine ants in an urban environment, ... sting may be the next invasive species to see ...
... MDIf you have an overactive bladder or incontinence, help could be ... FASEB Journal , shows that the epithelium, a ... is able to sense how full the bladder is through the ... bladder becomes full, the cells in the epithelium stretch and become ...
Cached Biology News:Studying bed bug actions for new management tactics 2Researchers find Asian needle ants displacing other aggressive invaders 2Got to go? Harvard scientists figure out how you know 2
... and PowerPac 3000 system, 220-240 V, is used ... 50 cm vertical slab gel format. The system ... is capable of separating nucleic acids with single ... (IPC) assembly (IPC and bonded inner glass plate, ...
... Plus overlay agarose is used for ... IPG strips in place in PROTEAN ... is incorporated to allow monitoring of ... of 0.75% agarose in 1x Tris, ...
... The PowerPac HV high-voltage power supply, with ... increased output of 5,000 V, 500 mA, and ... monitor gel temperature between 0 and 90 degrees ... wireless data transfer. Power cord and instructions are ...
The stirbar is used in the buffer tank of the Trans-Blot Plus cell to maintain uniform conductivity and temperature during electrophoretic transfer. Dimensions are 3.5 x 0.5 in....
Biology Products: